Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the pricing of a public offering expected to generate approximately $6.0 million in gross proceeds before fees and expenses, according to a company statement.

The offering consists of 12,000,000 Common Units or Pre-Funded Units priced at $0.50 per Common Unit and $0.49999 per Pre-Funded Unit. Each unit includes one share of common stock or one pre-funded warrant, plus two Series C Warrants to purchase common stock at an exercise price of $0.50 per warrant.

The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The Series C Warrants are exercisable immediately and expire five years after issuance. The exercise price and number of shares under the Series C Warrants are subject to adjustment.

The transaction is expected to close on or about May 19, 2026, subject to customary closing conditions. The company plans to use net proceeds for general corporate purposes and working capital.

Aegis Capital Corp. serves as the exclusive placement agent for the offering. A registration statement on Form S-1 filed with the Securities and Exchange Commission on May 12, 2026, was declared effective on May 18, 2026.

Sunshine Biopharma markets 60 generic prescription drugs in Canada and has 12 additional launches planned for 2026. The company is developing K1.1 mRNA, a therapeutic candidate targeting liver cancer, and PLpro protease inhibitor, an antiviral candidate for SARS-related coronavirus infections.